RWA Wealth Partners LLC Buys Shares of 3,120 Edwards Lifesciences Co. (NYSE:EW)

RWA Wealth Partners LLC bought a new stake in Edwards Lifesciences Co. (NYSE:EW) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 3,120 shares of the medical research company’s stock, valued at approximately $238,000.

Other institutional investors also recently made changes to their positions in the company. Turtle Creek Wealth Advisors LLC acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at approximately $34,000. Operose Advisors LLC increased its holdings in shares of Edwards Lifesciences by 247.0% in the 3rd quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 452 shares during the last quarter. SRS Capital Advisors Inc. increased its holdings in shares of Edwards Lifesciences by 292.6% in the 3rd quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 474 shares during the last quarter. NBC Securities Inc. bought a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at approximately $52,000. Finally, ORG Partners LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at approximately $66,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of research analyst reports. OTR Global upgraded Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. Citigroup upped their price objective on Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 3rd. Evercore ISI dropped their target price on Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a research report on Friday. Finally, Stifel Nicolaus increased their target price on Edwards Lifesciences from $83.00 to $85.00 and gave the stock a “hold” rating in a research report on Friday. One research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average target price of $93.33.

Edwards Lifesciences Trading Down 1.8 %

Shares of EW stock opened at $86.43 on Friday. The stock has a 50-day simple moving average of $90.28 and a 200 day simple moving average of $78.85. Edwards Lifesciences Co. has a fifty-two week low of $60.57 and a fifty-two week high of $96.12. The stock has a market capitalization of $52.02 billion, a P/E ratio of 37.58, a P/E/G ratio of 4.39 and a beta of 1.05. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The business had revenue of $1.60 billion during the quarter, compared to analysts’ expectations of $1.58 billion. On average, sell-side analysts expect that Edwards Lifesciences Co. will post 2.76 earnings per share for the current fiscal year.

Insider Activity at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares in the company, valued at approximately $1,506,925.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Heisz Leslie Stone sold 7,056 shares of the stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $86.45, for a total value of $609,991.20. Following the completion of the transaction, the director now owns 26,980 shares in the company, valued at approximately $2,332,421. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares of the company’s stock, valued at approximately $1,506,925.92. The disclosure for this sale can be found here. Insiders sold 194,004 shares of company stock valued at $17,166,254 over the last 90 days. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.